MedTrace Logo

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-02-15

No results posted yet for this study

Summary

Evaluation of safety, pharmacokinetics, and anti-psoriatic efficacy to assess SOR007 Ointment in topical formulations

Conditions

Interventions

DRUG

SOR007 Ointment 2.0%

DRUG

SOR007 Ointment 1.0%

DRUG

SOR007 Ointment 0.3%

DRUG

SOR007 Ointment 0.15%

DRUG

SOR007 Ointment Placebo

DRUG

Taclonex® Ointment

Sponsors & Collaborators

  • Bioskin GmbH

    collaborator INDUSTRY

  • US Biotest, Inc.

    collaborator INDUSTRY

  • DFB Soria, LLC

    lead INDUSTRY

Principal Investigators

  • Gere S diZerega, MD · US Biotest, Inc./DFB Soria, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-02-13
Completion
2017-02-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004339 on ClinicalTrials.gov